-DOCSTART- -X- O
Therapeutic -X- _ B-Intervention
vaccination -X- _ I-Intervention
of -X- _ I-Intervention
lymphoma -X- _ I-Intervention
patients -X- _ I-Intervention
with -X- _ I-Intervention
tumor-specific -X- _ I-Intervention
immunoglobulin -X- _ I-Intervention
( -X- _ I-Intervention
idiotype -X- _ I-Intervention
, -X- _ I-Intervention
Id -X- _ I-Intervention
) -X- _ I-Intervention
coupled -X- _ I-Intervention
to -X- _ I-Intervention
the -X- _ I-Intervention
carrier -X- _ I-Intervention
protein -X- _ I-Intervention
keyhole -X- _ I-Intervention
limpet -X- _ I-Intervention
hemocyanin -X- _ I-Intervention
( -X- _ I-Intervention
Id-KLH -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
undergoing -X- _ O
clinical -X- _ O
investigation -X- _ O
, -X- _ O
and -X- _ O
methods -X- _ O
to -X- _ O
improve -X- _ B-Outcome
the -X- _ I-Outcome
immunogenicity -X- _ I-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
and -X- _ I-Outcome
other -X- _ I-Outcome
protein -X- _ I-Outcome
tumor -X- _ I-Outcome
antigen -X- _ I-Outcome
vaccines -X- _ I-Outcome
are -X- _ O
being -X- _ O
sought. -X- _ O
Id -X- _ B-Intervention
proteins -X- _ I-Intervention
can -X- _ O
be -X- _ O
produced -X- _ O
via -X- _ O
tumor-myeloma -X- _ O
hybridomas -X- _ O
or -X- _ O
recombinant -X- _ O
methods -X- _ O
in -X- _ O
mammalian -X- _ O
, -X- _ O
bacteria -X- _ O
, -X- _ O
or -X- _ O
insect -X- _ O
cells. -X- _ O
We -X- _ O
now -X- _ O
demonstrate -X- _ O
that -X- _ O
terminal -X- _ B-Intervention
mannose -X- _ I-Intervention
residues -X- _ I-Intervention
, -X- _ O
characteristic -X- _ O
of -X- _ O
recombinant -X- _ O
proteins -X- _ O
produced -X- _ O
in -X- _ O
insect -X- _ O
cells -X- _ O
, -X- _ O
yield -X- _ O
Id -X- _ B-Intervention
proteins -X- _ I-Intervention
with -X- _ O
significantly -X- _ B-Outcome
enhanced -X- _ I-Outcome
immunostimulatory -X- _ I-Outcome
properties -X- _ I-Outcome
compared -X- _ B-Comparison
to -X- _ I-Comparison
Id -X- _ I-Comparison
proteins -X- _ I-Comparison
derived -X- _ I-Comparison
from -X- _ I-Comparison
mammalian -X- _ I-Comparison
cells. -X- _ I-Comparison
Recombinant -X- _ B-Intervention
baculovirus-infected -X- _ I-Intervention
insect -X- _ I-Intervention
cell-derived -X- _ I-Intervention
Id -X- _ I-Intervention
showed -X- _ O
higher -X- _ B-Outcome
binding -X- _ I-Outcome
to -X- _ I-Outcome
and -X- _ I-Outcome
activation -X- _ I-Outcome
of -X- _ I-Outcome
human -X- _ I-Outcome
dendritic -X- _ I-Outcome
cells -X- _ I-Outcome
mediated -X- _ I-Outcome
by -X- _ I-Outcome
mannose -X- _ I-Outcome
receptors. -X- _ I-Outcome
In -X- _ I-Outcome
vivo -X- _ I-Outcome
, -X- _ I-Outcome
insect -X- _ I-Outcome
cell-derived -X- _ I-Outcome
Id -X- _ I-Outcome
elicited -X- _ I-Outcome
higher -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
tumor-specific -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
CTL -X- _ I-Outcome
and -X- _ I-Outcome
improved -X- _ I-Outcome
eradication -X- _ I-Outcome
of -X- _ I-Outcome
pre-established -X- _ I-Outcome
murine -X- _ I-Outcome
lymphoma. -X- _ I-Outcome
Insect -X- _ B-Intervention
cell -X- _ I-Intervention
and -X- _ O
mammalian -X- _ B-Comparison
Id -X- _ I-Comparison
generated -X- _ O
similar -X- _ O
levels -X- _ O
of -X- _ O
tumor-specific -X- _ O
antibodies -X- _ O
, -X- _ O
showing -X- _ O
no -X- _ O
impairment -X- _ O
in -X- _ O
antibody -X- _ O
responses -X- _ O
to -X- _ O
native -X- _ O
tumor -X- _ O
antigen -X- _ O
despite -X- _ O
the -X- _ O
glycoslylation -X- _ O
differences -X- _ O
in -X- _ O
the -X- _ O
immunogen. -X- _ O
Combining -X- _ B-Outcome
insect -X- _ I-Outcome
cell -X- _ I-Outcome
production -X- _ I-Outcome
and -X- _ I-Outcome
maleimide-based -X- _ I-Outcome
KLH -X- _ I-Outcome
conjugation -X- _ I-Outcome
offered -X- _ I-Outcome
the -X- _ I-Outcome
highest -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
anti-tumor -X- _ I-Outcome
immunity. -X- _ I-Outcome
Our -X- _ O
data -X- _ O
comparing -X- _ O
sources -X- _ O
of -X- _ O
recombinant -X- _ O
Id -X- _ O
protein -X- _ O
tumor -X- _ O
antigens -X- _ O
used -X- _ O
in -X- _ O
therapeutic -X- _ O
cancer -X- _ O
vaccines -X- _ O
demonstrate -X- _ O
that -X- _ O
insect -X- _ B-Intervention
cell-derived -X- _ I-Intervention
antigens -X- _ I-Intervention
can -X- _ O
offer -X- _ O
several -X- _ O
immunologic -X- _ O
advantages -X- _ O
over -X- _ O
proteins -X- _ B-Comparison
derived -X- _ I-Comparison
from -X- _ I-Comparison
mammalian -X- _ I-Comparison
sources -X- _ I-Comparison
. -X- _ O

